EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have nasopharyngeal cancer that has come back or spread to other parts of the body.
- You have not had any previous treatment for this recurrence or spread.
- You are otherwise healthy enough to undergo chemotherapy, immunotherapy, and targeted therapy (good blood counts, liver and kidney function).
- You have at least one tumor that can be measured on scans.
- You are not pregnant and agree to use effective contraception during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
This trial tests a combination therapy that first wakes up the Epstein-Barr virus (EBV) in cancer cells and then uses an immune-boosting drug (PD-1 antibody) to help your body attack them. It is for people whose nasopharyngeal cancer has come back or spread to other parts of the body.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial is for people with nasopharyngeal cancer that has come back in the same area. It tests whether giving additional radiation right after chemo plus immunotherapy works better than waiting to see if more radiation is needed later.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.